tirzepatide and liver disease Tirzepatide- A novel therapeutic against metabolic dysfunction-associated steatotic (MASLD) tirzepatide fatty liver disease Management

14 Figure 27: CoEQ change from baseline at week 26, PIONEER 3 (FAS) CI = confidence interval

Our commitment to excellence and dedication to pushing the boundaries of scientific research is what sets us apart

Show some love by liking, sharing and commenting your views/thoughts

This was confirmed when the companys product I was taking in capsule form came out with a liquid form

Always confirm your prescribed volume with your licensed provider

The SURMOUNT evidence Tirzepatides trial record centers on SURMOUNT for weight management ( The New England Journal of Medicine , 2022) and SURMOUNT-OSA for obstructive sleep apnea (NEJM 2024)